D. Barry Crittenden

D. Barry Crittenden is an accomplished executive in clinical development with extensive experience in leading medical research and regulatory strategies. Currently serving as Executive Director of Clinical Development at Gilead Sciences since August 2024, Crittenden previously held the position of Vice President of Clinical Development at CymaBay Therapeutics and served in various roles at Terns Pharmaceuticals, including Executive Director of Clinical Research and Medical Affairs. Early career highlights include senior roles at Horizon and Amgen, alongside academic positions at NYU Langone Health and NYU School of Medicine. Crittenden holds an MD from the David Geffen School of Medicine at UCLA, a Master of Science in Clinical Investigation from the NYU Clinical and Translational Science Institute, and a Bachelor's degree in English and American Literature and Language from Harvard University.